University of Oxford takes great stride in fight against HIV with its launch of HIV vaccine trials

UK – Researchers from the University of Oxford have launched the first phase trials of a novel mosaic vaccine targeting a ‘broad range’ of HIV variants. The HIV-CORE 0052 trial, part of the European Aids Vaccine Initiative, will involve 13 healthy HIV-negative adults aged 18 to 65 years old who are not considered to be at a high risk of infection. Participants are expected to receive one dose of the vaccine known as the HIVconsvX followed by a further boost dose at four weeks. HIVconsvX, unlike other HIV vaccine candidates…

Read More